This media program highlights real-world outcomes from the ROCCA registry evaluating obecabtagene autoleucel and brexucabtagene autoleucel in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Yannis K. Valtis, MD
Advertisement
Yannis K. Valtis, MD, is an oncologist at Memorial Sloan Kettering Cancer Center focusing on leukemia and cellular therapy.
Articles by Yannis K. Valtis, MD
Yannis K. Valtis, MD, discusses real-world outcomes for obecabtagene autoleucel and brexucabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5